Table 1.

Clinicopathological characteristics of the high-risk endometrial cancer patient cohort.

	All patients		POLE-mutant		MSI		NSMP		p53-mutant
	N = 116		N = 15		N = 19		N = 42		N = 40
	N	%	N	%	N	%	N	%	N	%	p-value
Age at diagnosis (years)
Mean (range)	66 (21–85)		61 (49–80)		65 (49–82)		64 (21–84)		71 (45–85)		0.004
Stage
I	42	36.2	8	53.3	5	26.3	16	38.1	13	32.5	0.246
II	21	18.1	3	20.0	2	10.5	12	28.6	4	10.0
III	41	35.3	3	20.0	10	52.6	11	26.2	17	42.5
IV	11	9.5	1	6.7	2	10.5	3	7.1	5	12.5
Unknown	1	0.9	0	0.0	0	0.0	0	0.0	1	2.5
Tumor type
Endometrioid	86	74.1	14	93.3	17	89.5	35	83.3	20	50.0	<0.001
Serous	12	10.3	0	0.0	0	0.0	0	0.0	12	30.0
Clearcell	18	15.5	1	6.7	2	10.5	7	16.7	8	20.0
Grade
1	13	11.2	0	0.0	2	10.5	8	19.0	3	7.5	0.036
2	5	4.3	1	6.7	3	15.8	1	2.4	0	0.0
3	98	84.5	14	93.3	14	73.7	33	78.6	37	92.5
Lymphovascular space invasion
Yes	55	47.4	6	40	15	78.9	18	42.9	16	40	0.103
No	40	34.5	9	60.0	2	10.5	18	42.9	11	27.5
Unknown	21	18.1	0	0.0	2	10.5	6	14.3	13	32.5
Depth of myometrial invasion
<50%	23	19.8	4	26.7	2	10.5	6	14.3	11	27.5	0.261
>50%	87	75.0	11	73.3	17	89.5	33	78.6	26	65.0
Unknown	6	5.2	0	0.0	0	0.0	3	7.1	3	7.5
Adjuvant therapy
Yes	82	70.7	14	93.3	15	78.9	33	78.6	20	50.0	0.134
No	10	8.6	1	6.7	1	5.3	2	4.8	6	15.0
Unknown	24	20.7	0	0.0	3	15.8	7	16.7	14	35.0

Characteristics are shown for the whole group, as well as for each of the molecular subgroups analyzed. Abbreviations: MSI, microsatellite unstable; NSMP, no specific molecular profile.